Liver Cancer
An Introduction to Liver Cancer
The treatment of hepatic cell carcinoma holds numerous challenges, and there are currently limited treatment options with proven efficacy. Developments in the treatment landscape, including the introduction of several oral tyrosine kinase inhibitors, monoclonal antibodies and immune checkpoint inhibitors targeting PD-1 and PD-L1, have been important additions to improve patient outcomes. New potential treatments currently under investigation include A3 adenosine receptor (A3AR) agonists, fibroblast growth factor receptor 4 (FGFR4) inhibitors and multikinase inhibitors.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.